QQX — Respiratory Specimen Nucleic Acid Sars-Cov-2 Test Class II

FDA Device Classification

FDA product code QQX covers "Respiratory Specimen Nucleic Acid Sars-Cov-2 Test", a Class II medical device regulated under 21 CFR 866.3981. Submissions are reviewed by the Microbiology panel. At least 11 recent 510(k) clearances have been granted under this product code.

Classification Details

Product Code
QQX
Device Class
Class II
Regulation Number
866.3981
Submission Type
Review Panel
MI
Medical Specialty
Microbiology
Implant
No

Definition

A device to detect and identify nucleic acid targets in respiratory specimens from SARS-CoV-2 that cause COVID-19 is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 nucleic acid targets in human clinical respiratory specimens from patients suspected of COVID-19 based on signs and symptoms of respiratory infections by their healthcare providers. The device is intended to aid in the diagnosis of COVID-19 in conjunction with other clinical, epidemiologic, and laboratory data or other risk factors.

Recent 510(k) Clearances

K-NumberApplicantDevice NameDate
K243396hologicAptima SARS-CoV-2 AssayFebruary 13, 2025
K240867roche molecular systemscobas® SARS-CoV-2 Qualitative for use on the cobas® 5800/6800/8800 SystemsFebruary 11, 2025
K242109cepheid®Xpert® Xpress CoV-2 plus (XPRS-COV2-10)January 15, 2025
K241580abbott molecularAlinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m SARS-CoV-2 CTRL Kit (09N78-0December 6, 2024
K233453life technologies corporationApplied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR KitJuly 10, 2024
K230440cepheid®Xpert® Xpress CoV-2 plusOctober 13, 2023
K231306roche molecular systemscobas SARS-CoV-2 Qualitative for use on the cobas 5800/6800/8800 SystemsJune 1, 2023
K213804roche molecular systemscobas SARS-CoV-2 Qualitative for use on the cobas 6800/8800 SystemsOctober 22, 2022
K212147diasorin molecularSimplexa COVID-19 DirectSeptember 13, 2022
K221460biofire defenseBioFire COVID-19 Test 2July 25, 2022
K211079biofire defenseBioFire COVID-19 Test 2November 1, 2021